Ann Ginsberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ann Ginsberg has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Angeline Nanni
Aeras, 1405 Research Blvd., Rockville, MD 20850, USA
1 shared publication - David A. Hokey
Aeras
1 shared publication Helen McShane
Jenner Institute, University of Oxford, Oxford, UK
1 shared publication- Helen Mearns
Vaccines for Africa Initiative, University of Cape Town, Cape Town, South Africa
1 shared publication - Karin Holm
Patient Advocates for Cancer Research and Treatment (Association PACRT), Geneva, Switzerland
1 shared publication Morten Ruhwald
Statens Serum Institut, Copenhagen, Denmark
1 shared publication
Latest Publications
- Open Access
- 1 August 2016
- Published by Elsevier in Tuberculosis
- Vol. 99, S16-S20
TB vaccines in clinical development
- 1 August 2016
- Published by Elsevier in Tuberculosis
- Vol. 99, S16-S20
Open AccessTB vaccines in clinical development
- Open Access
- 4 October 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (10) , 2142-2146
The current state of tuberculosis vaccines
Tuberculosis continues to persist despite widespread use of BCG, the only licensed vaccine to prevent TB. BCG's limited efficacy coupled with the emergence of drug-resistant strains of Mycobacterium tuberculosis emphasizes the need for a more effective vaccine for combatting this disease. However, the development of a TB vaccine is hindered by the lack of immune correlates, suboptimal animal models, and limited funding. An adolescent/adult vaccine would have the greatest public health impact, but effective delivery of such a vaccine will require a better understanding of global TB epidemiology, improved infrastructure, and engagement of public health leaders and global manufacturers. Here we discuss the current state of tuberculosis vaccine research and development, including our understanding of the underlying immunology as well as the challenges and opportunities that may hinder or facilitate the development of a new and efficacious vaccine.
- 4 October 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (10) , 2142-2146
Open AccessThe current state of tuberculosis vaccines
Tuberculosis continues to persist despite widespread use of BCG, the only licensed vaccine to prevent TB. BCG's limited efficacy coupled with the emergence of drug-resistant strains of Mycobacterium tuberculosis emphasizes the need for a more effective vaccine for combatting this disease. However, the development of a TB vaccine is hindered by the lack of immune correlates, suboptimal animal models, and limited funding. An adolescent/adult vaccine would have the greatest public health impact, but effective delivery of such a vaccine will require a better understanding of global TB epidemiology, improved infrastructure, and engagement of public health leaders and global manufacturers. Here we discuss the current state of tuberculosis vaccine research and development, including our understanding of the underlying immunology as well as the challenges and opportunities that may hinder or facilitate the development of a new and efficacious vaccine.